Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Authors
Keywords
SGLT2 inhibitors, Type 2 diabetes, Diabetic cardiomyopathy, EMPA-REG OUTCOME, Cardiovascular
Journal
HEART FAILURE REVIEWS
Volume 23, Issue 3, Pages 419-437
Publisher
Springer Nature
Online
2018-01-11
DOI
10.1007/s10741-017-9665-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
- (2017) Asadur Rahman et al. HYPERTENSION RESEARCH
- Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target
- (2017) Alessandra Di Franco et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
- (2017) Tatsuya Fukuda et al. Diabetes Therapy
- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
- (2017) Tatsuya Fukuda et al. Diabetes Therapy
- Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia-reperfusion injury
- (2016) Abhinav Kanwal et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
- (2016) Hiroaki Kusaka et al. Cardiovascular Diabetology
- Executive Summary: Heart Disease and Stroke Statistics—2016 Update
- (2016) Dariush Mozaffarian et al. CIRCULATION
- Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes
- (2016) Manasi S. Shah et al. CIRCULATION RESEARCH
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus
- (2016) Anne Lejay et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2016) Theo Vos et al. LANCET
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
- (2016) Markus Scheerer et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
- (2015) Ying Han et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- In rats the duration of diabetes influences its impact on cardiac autonomic innervations and electrophysiology
- (2015) Yong-Li Xuan et al. AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL
- M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes
- (2015) Charlotte Roma-Lavisse et al. Diabetes & Vascular Disease Research
- 5. Glycemic Targets
- (2015) DIABETES CARE
- SGLT2 Inhibitors: The Latest “New Kids on the Block”!
- (2015) William T. Cefalu et al. DIABETES CARE
- Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
- (2015) Stephan Matthaei et al. DIABETES CARE
- Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
- (2015) Sunder Mudaliar et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
- (2015) R. Chilton et al. DIABETES OBESITY & METABOLISM
- Na+/Ca2+exchange and Na+/K+-ATPase in the heart
- (2015) Michael J. Shattock et al. JOURNAL OF PHYSIOLOGY-LONDON
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT-2 inhibition and glucagon: Cause for alarm?
- (2015) Richard G. Kibbey TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
- (2015) Wataru Ogawa et al. Journal of Diabetes Investigation
- Intracellular Na+Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+–Glucose Cotransport
- (2015) Rebekah Lambert et al. Journal of the American Heart Association
- Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study
- (2015) Lancet Diabetes & Endocrinology
- Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice
- (2015) Yusuke Kashiwagi et al. PLoS One
- Functional deficiencies of subsarcolemmal mitochondria in the type 2 diabetic human heart
- (2014) Tara L. Croston et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Diabetes, oxidative stress and therapeutic strategies
- (2014) Luc Rochette et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
- (2014) Bowen Lin et al. Cardiovascular Diabetology
- Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients
- (2014) David Montaigne et al. CIRCULATION
- Arachidonate 12/15-Lipoxygenase–Induced Inflammation and Oxidative Stress Are Involved in the Development of Diabetic Cardiomyopathy
- (2014) Hirofumi Suzuki et al. DIABETES
- Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
- (2014) Lawrence A. Leiter et al. DIABETES CARE
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Molecular mechanisms of diabetic cardiomyopathy
- (2014) Heiko Bugger et al. DIABETOLOGIA
- SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
- (2014) Masanori Yokono et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
- (2014) Nobuya Inagaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes
- (2014) Chris P. H. Lexis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
- (2014) Rury R Holman et al. LANCET
- Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats
- (2014) N. N. Hamouda et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- The pathophysiology of heart failure with preserved ejection fraction
- (2014) Barry A. Borlaug Nature Reviews Cardiology
- Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
- (2014) Ivana Vrhovac et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model
- (2014) Beibei Luo et al. PLoS One
- Activation of Toll-Like Receptors and Inflammasome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation
- (2014) J. Fuentes-Antrás et al. International Journal of Endocrinology
- Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
- (2014) M Suzuki et al. Nutrition & Diabetes
- Ketone body metabolism and cardiovascular disease
- (2013) David G. Cotter et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Endothelial dysfunction — A major mediator of diabetic vascular disease
- (2013) Cristina M. Sena et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- The NLRP3 Inflammasome and Diabetic Cardiomyopathy
- (2013) Lalit P. Singh CARDIOVASCULAR DRUGS AND THERAPY
- Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model
- (2013) Beibei Luo et al. CARDIOVASCULAR DRUGS AND THERAPY
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- N-Acetylcysteine and allopurinol up-regulated the Jak/STAT3 and PI3K/Akt pathways via adiponectin and attenuated myocardial postischemic injury in diabetes
- (2013) Tingting Wang et al. FREE RADICAL BIOLOGY AND MEDICINE
- Na+ transport in the normal and failing heart — Remember the balance
- (2013) Sanda Despa et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Obesity and the Obesity Paradox in Heart Failure
- (2013) Adrienne L. Clark et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
- (2012) Daisuke Shiraishi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The pathophysiology of heart failure
- (2012) Clinton D. Kemp et al. CARDIOVASCULAR PATHOLOGY
- Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular Remodeling
- (2012) Saumya Das et al. CIRCULATION
- Acute Hyperglycemia in Patients With Acute Myocardial Infarction
- (2012) Masaharu Ishihara CIRCULATION JOURNAL
- Increased Myocardial Uptake of Dietary Fatty Acids Linked to Cardiac Dysfunction in Glucose-Intolerant Humans
- (2012) S. M. Labbe et al. DIABETES
- Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?
- (2012) J. Liu et al. DIABETES
- Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1
- (2012) Florian Lang et al. FASEB JOURNAL
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy
- (2012) Changwon Kho et al. Nature Reviews Cardiology
- Cardiovascular autonomic neuropathies as complications of diabetes mellitus
- (2012) Michael Kuehl et al. Nature Reviews Endocrinology
- Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
- (2012) James J. Devenny et al. Obesity
- Suppression of Oxidative Stress by -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
- (2012) T. Shimazu et al. SCIENCE
- The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
- (2011) Beckley K. Davis et al. Annual Review of Immunology
- NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1
- (2011) Magali Balteau et al. CARDIOVASCULAR RESEARCH
- A Murine Model of Isolated Cardiac Steatosis Leads to Cardiomyopathy
- (2011) Denis J. Glenn et al. HYPERTENSION
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
- (2011) Bolormaa Vandanmagsar et al. NATURE MEDICINE
- Oxidative stress: a key contributor to diabetic cardiomyopathyThis review is one of a selection of papers published in a Special Issue on Oxidative Stress in Health and Disease.
- (2010) Madhu Khullar et al. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
- Metabolic memory: a vascular perspective
- (2010) Thomas W Jax Cardiovascular Diabetology
- Admission glucose level and in-hospital outcomes in diabetic and non-diabetic patients with acute myocardial infarction
- (2010) Artur Dziewierz et al. Clinical Research in Cardiology
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Autonomic imbalance: prophet of doom or scope for hope?
- (2010) A. I. Vinik et al. DIABETIC MEDICINE
- Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice
- (2010) Masaya Fukuda et al. JOURNAL OF HYPERTENSION
- Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes
- (2010) Luuk J. Rijzewijk et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
- (2010) Peter Duewell et al. NATURE
- Molecular mechanisms of diabetic vascular complications
- (2010) Munehiro Kitada et al. Journal of Diabetes Investigation
- Admission and fasting plasma glucose for estimating risk of death of diabetic and nondiabetic patients with acute coronary syndrome: nonlinearity of hazard ratios and time-dependent comparison
- (2009) Belen Cid-Alvarez et al. AMERICAN HEART JOURNAL
- Elevated plasma levels of TNF-alpha and Interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders
- (2009) Wilfried Dinh et al. Cardiovascular Diabetology
- SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states
- (2009) S. K. Banerjee et al. CARDIOVASCULAR RESEARCH
- Role of mitochondrial dynamics proteins in the pathophysiology of obesity and type 2 diabetes
- (2009) Antonio Zorzano et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Altered Myocardial Substrate Metabolism and Decreased Diastolic Function in Nonischemic Human Diabetic Cardiomyopathy
- (2009) Luuk J. Rijzewijk et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Substrate-Specific Derangements in Mitochondrial Metabolism and Redox Balance in the Atrium of the Type 2 Diabetic Human Heart
- (2009) Ethan J. Anderson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach?
- (2008) M AVKIRAN et al. CURRENT OPINION IN PHARMACOLOGY
- A Functional Role for Sodium-Dependent Glucose Transport across the Blood-Brain Barrier during Oxygen Glucose Deprivation
- (2008) S. Vemula et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Glucose and Glucose Transporters Regulate Lymphatic Pump Activity through Activation of the Mitochondrial ATP-Sensitive K+ Channel
- (2008) Xiangjun Li et al. Journal of Physiological Sciences
- Myocardial Steatosis Is an Independent Predictor of Diastolic Dysfunction in Type 2 Diabetes Mellitus
- (2008) Luuk J. Rijzewijk et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats
- (2008) Wenyuan Zhao et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started